학술논문
Intracerebroventricular administration of vasoactive intestinal peptide inhibits food intake.
Document Type
Academic Journal
Author
Ghourab S; Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Imperial College London, Du Cane Road, London, W12 0NN, UK. s.ghourab06@imperial.ac.uk; Beale KE; Semjonous NM; Simpson KA; Martin NM; Ghatei MA; Bloom SR; Smith KL
Source
Publisher: Elsevier/North Holland Country of Publication: Netherlands NLM ID: 8100479 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-1686 (Electronic) Linking ISSN: 01670115 NLM ISO Abbreviation: Regul Pept Subsets: MEDLINE
Subject
Language
English
Abstract
Vasoactive intestinal peptide (VIP) is a 28 amino acid peptide expressed throughout the peripheral and central nervous systems. VIP and the VIP receptor VPAC(2)R are expressed in hypothalamic nuclei involved in the regulation of energy homeostasis. VIP has been shown to be involved in the regulation of energy balance in a number of non-mammalian vertebrates. We therefore examined the effects of intracerebroventricular (ICV) administration of VIP on food intake, energy expenditure and activity in adult male Wistar rats. VIP administration caused a potent short lived decrease in food intake and an increase in activity and energy expenditure. The pathways potentially involved in the anorexigenic effects of VIP were investigated by measuring the release of neuropeptides involved in the regulation of food intake from hypothalamic explants treated with VIP. VIP significantly stimulated the release of the anorexigenic peptide alpha-melanocyte stimulating hormone (αMSH). These studies suggest that VIP may have an endogenous role in the hypothalamic control of energy homeostasis.
(Copyright © 2011 Elsevier B.V. All rights reserved.)
(Copyright © 2011 Elsevier B.V. All rights reserved.)